• About
  • Team
  • Portfolio
  • News
  • Contact
June 26, 2019 in Uncategorized by Christophe Guichard 0 Comments

PNAS publication supports temelimab’s rationale against neurodegeneration in MS

Research supports neurobiological rationale for evidence of neuroprotection obtained in completed Phase 2b clinical trials Protective effects on axonal degeneration and remyelination support potential role of teme ...

June 24, 2019 in Uncategorized by Christophe Guichard 0 Comments

Final Data Analysis of Phase 2 PBC Trial Shows that Genkyotex’s Anti-fibrotic Candidate GKT831 Demonstrated Statistically Significant Improvements in GGT and ALP Over Full Treatment Period

Statistically significant reductions in GGT and ALP in 400mg BID dose over 24-week treatment period (p<0.002 and p<0.001, respectively) GKT831 400mg BID significantly improved multiple quality of life metric ...

Eclosion

Campus Biotech
Innovation Park
Bâtiment F2
Av. Sécheron 15
1201 Geneva
Suisse

Tel: +41 (0)22 544 29 34

    Logo
    Eclosion Ventures © 2021 | Crédits